Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study

Authors
Category Primary study
JournalBRITISH JOURNAL OF DERMATOLOGY
Year 2024
This article has no abstract
Epistemonikos ID: c6395b7ee66bf807b2fdbea33763b59f0dad39e2
First added on: Feb 18, 2025